Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
26 results
D1.76 - Contact dermatitis in diabetic patients with wearable devices: A single-centre study
D1.87 - Kiwi allergy: A Comparative Analysis of Adult and Pediatric patients
D1.77 - Hereditary Angioedema in Real Life: Unmet Needs from the Patient Perspective
D1.78 - Non-Allergic Dermatologic Diagnoses Among Patients Presenting to an Allergy Immunology Outpatient Clinic: A Prospective Clinical Study
D1.79 - Heterogeneity of Non-Allergic Non-Eosinophilic Asthma: Clinical Subphenotypes and Allergy Belief Patterns
D1.82 - Pancake Syndrome: Molecular and Diagnostic Heterogeneity of Mite Sensitization
D1.83 - Cannabis-related severe anaphylaxis without cutaneous manifestations: atypical sensitization profile and mast cell disorder differential diagnosis in a case report
D1.84 - Invasion Meets Allergy: Cortaderia selloana as an Emerging Grass Aeroallergen
D1.85 - Baseline lung function and clinical outcomes in Allergic Bronchopulmonary Mycosis: A real-world cohort from a Severe Asthma Multidisciplinary Unit
D1.86 - Age-Related Features of Sensitization to Timothy Grass in Children According to Component-Resolved Diagnostics
D1.88 - An unusual diagnostic aid for Hymenoptera venom genuine versus cross sensitization: the field sting
D1.89 - Qualitative comparison between Euroline Respiratory Profile and Phadiatop for the screening of airborne allergies
D1.105 - Real-Life Evidence of Type 2 Immunomodulation with Benralizumab: From Steroid-Dependent to Controlled Asthma
D1.106 - Dupilumab-Induced Systemic Eosinophilic Immune Activation Mimicking an EGPA-Like Prodrome: A Case Report
D1.108 - Optimization of phenotyping in severe T2-bronchial asthma
D1.109 - Biologics selection algorithm for severe T2-bronchial asthma targeted therapy
D1.110 - Long Term Mepolizumab in Type-2 CRSwNP: Marked Polyp Reduction, Symptom Relief, and Airway Benefits in Real World Comorbid Patients
D1.111 - Tezepelumab reduces in patients with severe allergic asthma and rhinoconjunctivitis not only bronchial but also nasal and conjunctival symptoms – results from an exposure chamber study
D1.112 - ILC2 Expansion as a Biomarker of Suboptimal Response to Dupilumab in Severe Asthma: Findings from the PRISM Study
D1.113 - Effect of mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA): a real-world retrospective observational study
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download